Harrow Health Inc Stock Price, News & Analysis

Harrow Health (NASDAQ: HROW) reported exceptional financial results for Q3 2020, marking the best quarter in its history. Revenues increased month-over-month, achieving record gross margins and adjusted EBITDA. CEO Mark L. Baum expressed optimism about a continuous upward revenue trend heading into 2021, anticipating potential value inflection events. The company primarily focuses on ophthalmology through ImprimisRx and owns significant stakes in several pharmaceutical entities. A conference call discussing these results will be held on Nov. 9, 2020.

Harrow Health (NASDAQ: HROW) will announce its third quarter 2020 financial results after the market closes on November 9, 2020. A conference call will follow at 4:45 p.m. EST, providing an overview of the quarter and future outlook. Investors can access a press release and the company's Letter to Stockholders on its Investor Relations website. The call is intended for analysts to engage with the management team. Replay options for the call will be available until December 9, 2020, for dial-in listeners and until February 9, 2021, for webcast listeners.

Harrow Health (NASDAQ: HROW) will attend Lake Street’s 4th Annual Best Ideas Growth Conference on September 17, 2020, via a virtual platform. CEO Mark L. Baum and CFO Andrew Boll will be available for one-on-one meetings with investors throughout the day to discuss business updates. Interested parties should contact their Lake Street representative to arrange meetings or email conference@lakestreetcm.com for more information. Harrow Health owns a portfolio of healthcare businesses focused on patient-first solutions.

Harrow Health, Inc. (NASDAQ: HROW) announced its second quarter 2020 results, reporting a swift recovery post-COVID-19 impact. CEO Mark L. Baum highlighted record-high revenue days in Q3, attributed to effective product formulations and a new partnership with EyePoint Pharmaceuticals to market DEXYCU®. The company anticipates significant catalysts from Eton, Surface, and Melt in the coming months, bolstering optimism for shareholders.

Harrow Health (NASDAQ: HROW) will release its second quarter 2020 financial results on August 10, 2020, following the market close. A conference call is scheduled for 5:00 PM EDT to discuss these results and recent business developments. The press release will also include a link to the second quarter Letter to Stockholders, available on the Investor Relations website. A replay of the conference call will be accessible until September 10, 2020, with a webcast replay available until November 10, 2020.

Harrow Health (NASDAQ: HROW) announced positive findings from a randomized eye study conducted by its subsidiary ImprimisRx. The study compared patient outcomes using a combination eye drop versus individual drops post-cataract surgery. Results showed the combination drop, which includes prednisolone acetate, gatifloxacin, and bromfenac sodium, demonstrated similar health outcomes with unanimous patient preference for ease of use. The study, published in Clinical Ophthalmology, highlights ImprimisRx's commitment to improving patient compliance and satisfaction with ocular treatments.

Harrow Health, Inc. (HROW) announced that Florida's optometrists can now prescribe its Klarity-C formulation, a preservative-free 0.1% cyclosporine emulsion, following recent updates to the state’s Formulary of Topical Ocular Pharmaceutical Agents. This product has already been prescribed across all 50 states. ImprimisRx, a subsidiary of Harrow, emphasizes the affordability and accessibility of its formulations without the complexities of prior authorizations or co-pays. Klarity-C has gained recognition at the ASCRS Annual Meeting for its efficacy in treating dry eye conditions.

Harrow Health, Inc. (NASDAQ: HROW) announced its first quarter 2020 results, highlighting its optimistic outlook as segments of the economy recover. CEO Mark L. Baum expressed confidence in the ImprimisRx team's ability to support physicians and improve health outcomes. The company has seen orders resume as customers re-open. Upcoming catalysts and developments are discussed in the Letter to Stockholders. A conference call is scheduled for today at 5:00 p.m. EDT for investors and analysts to engage with management.